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Antiretroviral effect of thiolated nucleotide 4-thio-uridylate (S4UMP, desig-
nated as UD29) against human immunodeficiency virus type 1 (HIV-1) have been
quantitatively determined in cell-based viral infectivity assays. In syntitium inhibition
assay on MT-2 human T-cell line UD29 prevented cell fusion and formation of syntitia
induced by HIV-1IIIB with IC50 values of 11.7 µg/ml. In a single-cycle viral infection
assay (MAGI assay) UD29 proved to have a potent inhibitory effect against HIV-1IIIB
on HeLaCD4-LTR/b-gal cells, which was dose dependent with IC50 values of 4.75
µg/ml and IC90 of 39.7 µg/ml. UD29 showed a most prominent antiviral effect when
administered 30 min prior HIV-1 infection. As HIV entry requires thiol/disulfide ex-
change process, results suggest that reactive –SH group of enol-form of the thiolated
nucleotide may interfere with the function of cell surface proteins. UD29 cannot pene-
trate into cells and may have an interactive role in redox processes active in viral entry.
Keywords: HIV infection, thiolated nucleosides, redox system, entry inhibi-
tor, infectivity assays
Introduction
Human immunodeficiency virus type 1 (HIV-1) infection and AIDS are se-
rious public health issues, as there are more than 35 million people worldwide
with HIV-1 infection or AIDS, according to estimates by the Joint United Nations
Programme on HIV/AIDS (UNAIDS) [1].
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The introduction of highly active antiretroviral therapy (HAART) has dra-
matically reduced morbidity and mortality of patients infected with HIV-1 [2].
The success of antiretroviral treatment, however, is limited by the emergence of
HIV-1 drug resistance, and by the fact that the drugs (which are inhibitors of
virally coded enzymes) used so far act only while the virus already infected the
cells.
The effort to identify therapeutic targets and develop effective treatment [3]
has led to extensive characterization of HIV and a better understanding of its repli-
cation cycle. The life cycle of retroviruses, including HIV is divided into two dis-
tinct phases: the early phase refers to the steps of infection from cell binding to the
integration of the viral cDNA into the cell genome, whereas the late phase begins
with the expression of viral genes and continues through to the release and matura-
tion of progeny virions.
The first clinically used effective inhibitor of HIV replication was the
nucleoside analogue, azido-thymidine (AZT) inhibiting the virus coded reverse
transcriptase (RT); later several other nucleoside analogues were developed with
the same mode of action. For sensitive detection of AZT, we have developed a
specific radioimmuno-assay [4]. A new class of therapeutic HIV inhibitor was de-
veloped, the non-nucleoside RT inhibitors (NNRTI). Later, another HIV enzyme,
protease (PR) paved the way for the development of new class of antiviral agents:
protease inhibitors [5]. Today these classes of inhibitors are the bases of the
HAART that has considerably extended the lifespan of many HIV patients. How-
ever, the frequent development of resistance towards these drugs limits their thera-
peutic application, as we analyzed it recently in Hungary [6, 7].
RT and PR inhibitors target HIV enzymes while virus infection has oc-
curred, and HIV already entered into the susceptible cells. The most effective
anti-HIV compounds should inhibit HIV entry into cells [8]. This initiated a more
extensive study on the early steps of HIV infection and the virus-cell interactions.
However, in comparison with the later events of HIV infection, early steps: HIV
entry, the mechanism of receptor binding, conformational changes and fusion are
still poorly understood [9]. Fully elucidating the early steps of HIV replication is
therefore crucial, not only for identifying new antiretroviral drugs, but also for im-
proving the design of retroviral vectors for gene therapy.
The first step in the primary infection is HIV-1 entry into host cells medi-
ated by its envelope glycoprotein (Env). The mature HIV envelope is composed of
the surface glycoprotein (gp)120 and transmembrane gp41 subunits [10]. HIV
binding to CD4+ lymphocytes is initiated by gp120 interaction with cell surface
CD4 (the primary receptor for HIV), which creates a high affinity binding site on
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gp120 for the chemokine coreceptor CXCR4 (or in the case of macrophages,
CCR5) [11]. Interactions between gp120 and the receptors lead to extensive
conformational changes within Env that eventually promote the unmasking of the
fusion peptide present on gp41. These conformational changes lead to the fusion
of viral and cell membranes allowing HIV to get into cytoplasm [12]. An inhibitor
of gp41 (Enfuvirtide/T20) has recently been approved for therapeutic use in com-
bination therapy as HIV entry inhibitor [13].
In addition to conformational changes in cell surface receptors, coreceptors
of HIV and viral envelope proteins, redox changes in these proteins are also re-
quired for successful HIV-1 entry and infection. Several inhibitors of protein
disulfide isomerase (PDI) as well as cell-surface-thiol interacting agents including
thioredoxin, influence HIV infection [14, 15] indicating that redox processes ac-
tive in viral entry could be potential targets for treatment of HIV infection, as we
and others reported earlier [14–18].
In this paper we extend the earlier study on the antiretroviral activity of
4-thio-uridylate (designated as UD29) [16] measuring its inhibitory activity in cell
infectivity assays.
Materials and Methods
Preparation of thiolated uridylate (S4UMP, UD29)
The 4-thio uridylate (designated as UD29) was prepared by H2S treatment
of cytidine 5’-monophosphate, as described for oligonucleotides [18], and was
provided by Dr. Janos Aradi, University of Debrecen. A 20 mM (6.66 mg/ml)
aqueous stock solution of UD29 was prepared and kept at –20º C. It was diluted to
the required concentration with tissue culture media before use. In UD29 the
4-thiono group has a propensity toward tautomeric conversion to form a reactive
–SH, which may affect redox processes [16] (see Fig. 1). It is soluble in water, tis-
sue culture fluid, and the solution is stable at 4ºC for 15 days. Stock solution has
been sterilised by filtration. The UD29 solutions are slightly light sensitive.
Cells and viruses
H9 human T-cell line, MT-2 human T-cell line and HeLaCD4-LTR/b-gal
cell lines were obtained from the NIH AIDS Research and Reference Reagent Pro-
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gram (Bethesda, MD). H9 and MT-2 cell were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum, 2 mM l-glutamine and antibiotics.
HeLaCD4-LTR/b-gal cells were cultured in DMEM, 10% fetal calf serum, 2 mM
L-glutamine and antibiotics.
Human immunodeficiency virus type 1 (HIV-1IIIB) was obtained from
R. Weiss (London University, London, UK).
HIV-1IIIB stocks
The HIV-1IIIB strains were propagated in H9 human permanent T lympho-
cyte cells. HIV-1IIIB stocks were prepared from 24-h supernatants of freshly in-
fected H9 cells at 4 to 6 days after infection. Infectious titer was determined by
infectivity assays on MT-2 human T cells (see below). Supernatants with titers of
2.1 × 105 IU/ml were filtered through a 0.45 µ pore size filter (Millipore) and
stored at –70°C.
HIV-1 infectivity assays
Syncytium induction and inhibition assays on MT-2 cells
The infectious units of biologically active HIV-1 were determined by their
ability to induce syncytia (multinucleated giant cells or big balloon cells) [19, 20]
on MT-2 human T-cell line. Cells were cultured in a completed RPMI 1640 me-
dium and seeded in a 24-well plate (8 × 104 cell/well) , and various dilutions of
HIV-1 stock (prepared according to our published method [5]) were added. Ap-
pearance of syncytia was counted 48 h post infection. The possible inhibitory ac-
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Figure 1. Structure of 4-thio-uridylate (s4UMP, UD29); keto- and enol-tautomers
tivity on syncytia formation of the thiolated compounds (UD29) was quantita-
tively determined by adding the compounds in various concentrations (1, 2.5, 5,
10, 20, 40 µg/ml, respectively) to the cells 30 min before, at the time and 30 min
after virus infection. Reduction in the numbers of syncytia compared to the one
without UD29 treatment was calculated.
Quantitative HIV-1 p24 core antigen assay
Presence of HIV-1 core protein p24 in the supernatant of MT-2 cells upon
infection with HIV-1 stock, and the reduction of the concentration of HIV-1 p24
upon addition of the thiolated nucleotide (UD29) in various concentrations (see
above) before, at the time and after HIV-1 infection was quantitatively determined
by a HIV-1 p24 core antigen ELISA (BioMérieux, France).
Multinuclear activation of galactosidase inhibition (MAGI) assay
Infectious titer of HIV-1 has also been determined by the MAGI assay, as
we previously published [5]. Basically HeLaCD4-LTR/b-gal cells was seeded in
24-well plates and infected with a multiplicity of infection (moi) of 0.02, 0.2, and
0.4, respectively, of HIV-1 stock virus in the presence or in the absence of various
concentrations (1, 2.5, 5, 10, 20, 40 µg/ml, respectively) of UD29 . UD29 was
added to the cells 30 min before, at the time and 30 min after virus infection. Forty
hours after infection, infected cells were counted in situ with light microscope by
virtue of their blue color after incubation with 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-gal). Per cent inhibition was calculated as mean numbers of
blue cells of inhibitor-treated versus non-treated cultures using Hill analysis.
Statistical methods
For the determination of UD29 inhibitory concentrations IC50 and IC90 val-
ues Hill analysis with 95% confidence limit was used. For other biostatistical anal-
ysis two-tailed Student’s test was used.
XTT Assay measuring cytotoxicity
Prior to infectivity assays, the potential toxic effect of UD29 compound on
HeLaCD4-LTR/b-gal cells has been determined quantitatively in vitro by XTT
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based Toxicology Assay Kit (Sigma-Aldrich), which is a spectrophotometric
measurement of cell viability based on mitochondrial dehydrogenase activity in
living cells. The mitochondrial dehydrogenases of viable cells reduce the
terazolium ring of XTT (2,3-bis/2-Mthoxy-4-nitro5-sulphophenyl/-2H-terazo-
lium-5-carboxyanilide inner salt) yielding an orange formazane derivative.
Absorbance of converted dye is measured at a wavelength of 450 nm. During XTT
assay to measure cytotoxicity each well contained 125 µl (DMEM, 10%FCS,
Pen/Str) volume. The incubation period was 48 hours. At test all of the media was
removed and 100 µl DMEM was added. 20% of dissolved XTT reagent
(Sigma-Aldrich) was added to the media. Incubation time prior to measuring was
2.5 hours. Assay was performed according to the protocol.
Results
UD29 effect on cell viability
For analyzing possible antiviral effect of the thiolated uridylate in vitro, its
potential cytotoxicity on cell viability was determined on MT-2 human T lym-
phoid cells as well as quantitatively on HeLaCD4-LTR/b-gal cells (Fig. 2). The
acute (24 h) and chronic (48 h) cytotoxicity of the UD29 compound was deter-
mined by XTT Assay (Sigma-Aldrich), that measures metabolic activity, and is
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Figure 2. Toxicity of UD29 on HeLaCD4-LTR/b-gal cells
UD29 was administered at the indicated concentration to the monolayer cell cultures, and incubated
for 48 h. XTT assay, absorbance was read at 450 nm
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suitable for analyzing proliferation, viability, and cytotoxicity. There was no de-
tectable cytotoxicity (morphologically or by formazan dye reduction) when as
high as 200 µg/ml doses were utilized demonstrating that UD29 is a relatively
non-cytotoxic nucleotide analogue.
Antiviral activity of UD29 in cell based infectivity assays in vitro
Inhibition of cell fusion on MT-2 cells
When added to MT-2 human T-cells 30 min prior infection with HIV-1IIIB
strain, UD29 prevented formation of syncytia (multinucleated giant cell and/or
“balloon” cells without cell structures) (Fig. 3). Quantitative determination of
HIV-1 p24 core protein in the supernatant of virus infected MT-2 cells with and
without treatment of indicated UD29 concentrations demonstrated that UD29
showed an activity on inhibition of HIV-1IIIB induced cell fusion with IC50 values
of 11.7 µg/ml (Table II).
Inhibitory effect of UD29 on a single cycle infection with HIV-1IIIB
of HeLaCD4-LTR/b-gal cells
Now inhibition of HIV-1 replication by UD29 was assessed in standard
cell-based assay, such as the MAGI assay. HeLaCD4-LTR/b-gal cells have been
Acta Microbiologica et Immunologica Hungarica 59, 2012
ANTIRETROVIRAL EFFECT OF 4-THIO-URIDYLATE AGAINST HIV 505
Table I
Inhibitory effect of UD29 on a single cycle infection of HeLaCD4-LTR/b-gal cells
infected with HIV-1IIIB
Concentration of UD29 % inhibition
a
µg/ml –30 min at infection +30 min
1 2 2 <1
2.5 40 19 2
5 46 26 5
10 81 32 7
20 85 39 8
40 91 48 9
IC50 4.75 µg/ml >40 µg/ml >40 µg/ml
IC90 39.7 µg/ml >40 µg/ml >40 µg/ml
a Inhibitor was added to the cultures at indicated time intervals before, at the time and after infection with vi-
rus. b-galactosidase enzyme expression was quantitatively determined (see Materials and Methods), and per
cent inhibition was calculated using Hill analysis. Results are representative of multiple antiviral assays with
values shown as means of triplicates. Standard deviation was ± 5.8%.
treated with various concentration of UD29 (1–40 µg/ml) 30 min before, at the
time and 30 min after infection of cells with HIV-1IIIB virus of 0.02, 0.2, and 0.4
moi. HeLa cell construct allows only a single cycle of virus infection, therefore it
is suitable to test compounds with a potential of inhibiting viral entry. Forty hours
after virus infection b-galactosidase enzyme expression was quantitatively deter-
mined (see Materials and Methods), and per cent inhibition as well as IC50 and IC50
values were calculated using Hill analysis. UD29 showed a most prominent antivi-
ral effect when administered 30 min prior to HIV-1 infection (Table I). UD29
proved to have a potent inhibitory effect against HIV-1IIIB on HeLaCD4-
LTR/b-gal cells, which was dose dependent with IC50 values of 4.75 µg/ml and
IC90 of 39.7 µg/ml (Table I). It was noted, that its antiviral activity was more pro-
nounced in the infectivity (MAGI) assay than UD29 inhibitory effect on cell fu-
sion (Table II).
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Table II
Antiviral activity of UD29 against HIV-1IIIB: assessment for inhibition cell fusion and virus entry
IC50
a TC50
b TIc
Cell fusion 11.7 µg/ml >200 > 17
Viral entryd 4.75 µg/ml > 200 > 42
a 50% inhibition of virus infection
b 50% reduction in cell viability
c In vitro therapeutic index
d In MAGI assay
Figure 3. Inhibition of formation of syntitia (arrows) i.g. HIV-1IIIB virus infected MT-2 cells
upon treatment with UD29. A: virus infected, untreated cells, B: MT-2 cells treated with UD29
(10 µg/ml) 30 min prior to viral infection. No syncyitia were formed
A B
Discussion
To elucidate the exact inhibitory mechanism of UD29 a time-of-addition
experiment was performed. This experimental approach was able to specifically
identify the stages of viral life cycle targeted by thiolated uridylate, UD29. It was
shown that maximal inhibitory activity was observed when the drug (UD29) was
added prior to HIV-1 infection, in both syntitium, and in infectivity (MAGI) as-
says. When UD29 was added after virus infection its inhibitory activity was re-
duced significantly (Table I). This result suggests that the inhibitory activity on vi-
rus infection was exerted during early stage of viral life cycle, most likely, in the
entry process. Moreover, as UD29 is a nucleotide, its cellular uptake is not likely,
it cannot penetrate into the cells, therefore its activity should be associated with
events on the cell surface, virus-cell binding, and/or the entry.
In addition to conformational changes in cell surface receptors, coreceptors
of HIV (CD4, CCR5, and CXCR4) and viral envelope proteins (gp120, gp41), re-
dox changes in these proteins are also required for successful HIV entry [21–28].
Specifically, (1) the reduction of the second domain of CD4 was reported to be an
obligatory step in CD4-dependent fusion [25]; (2) two of the nine disulfide bonds
of gp120 must be reduced in order to promote the successful HIV entry [23, 28].
UD29 is chemically a thiolated nucleotide, in which the enol form of the com-
pound (Fig. 1) contains a reactive –SH group. It was shown earlier that UD29 is an
inhibitor of glyceraldehyde-phosphate dehydrogenase (GAPDH) [16], likely in-
terfering with the function of the essential –SH group in the active centre of the en-
zyme. The interfering effect of the –SH group of the nucleotide with protein –SHs
could be the bases of the HIV entry inhibitory activity of UD29, verified by our
time-of-addition experiment. UD29 may affect the redox changes of the second
domain of CD4 and/or the proper reduction of the disulfide bonds of gp120. The
proposed mode of action is in good agreement with results of the time-of-addition
experiments and with the syncytia formation assay. The formation of syncytia re-
quires active membrane reorganization in which cell membrane redox processes
are likely to be also involved.
It must be noted that UD29 is a mononucleotide, however, its deoxyoligo-
nucleotide derivatives are also active biologically inhibiting the HIV entry and the
telomerase enzyme [18, 29, 30]. Preliminary results on the activity of some other
derivatives of the thiolated nucleotide and polynucleotide have also been reported
[31].
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In summary, UD29 is a new HIV entry inhibitor acting on the cell surface,
likely affecting the redox modifications of receptors and viral proteins. This
mechanism has not been exploited yet for the treatment of HIV infection.
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